» Articles » PMID: 33892842

Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New

Overview
Specialties Neurology
Pediatrics
Date 2021 Apr 24
PMID 33892842
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease.

Citing Articles

Clinical Profile and Pulmonary Function of Pediatric Patients with Duchenne Muscular Dystrophy at a Tertiary Government Hospital.

Arquillo M, Layug E, Lozada M, Bautista K, Calotes-Castillo L Acta Med Philipp. 2025; 58(21):49-59.

PMID: 39758300 PMC: 11694038. DOI: 10.47895/amp.vi0.7975.


Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.

Krishna L, Prashant A, Kumar Y, Paneyala S, Patil S, Ramachandra S Neurol Int. 2024; 16(4):731-760.

PMID: 39051216 PMC: 11270304. DOI: 10.3390/neurolint16040055.


Assessing the Benefits and Harms Associated with Early Diagnosis from the Perspective of Parents with Multiple Children Diagnosed with Duchenne Muscular Dystrophy.

Bhattacharyya O, Campoamor N, Armstrong N, Freed M, Schrader R, Crossnohere N Int J Neonatal Screen. 2024; 10(2).

PMID: 38651397 PMC: 11036293. DOI: 10.3390/ijns10020032.


The complex landscape of DMD mutations: moving towards personalized medicine.

Gatto F, Benemei S, Piluso G, Bello L Front Genet. 2024; 15:1360224.

PMID: 38596212 PMC: 11002111. DOI: 10.3389/fgene.2024.1360224.


Cross-species modeling of muscular dystrophy in Caenorhabditis elegans using patient-derived extracellular vesicles.

Shalash R, Levi-Ferber M, Cohen C, Dori A, Brodie C, Henis-Korenblit S Dis Model Mech. 2024; 17(3).

PMID: 38501170 PMC: 11007864. DOI: 10.1242/dmm.050412.